0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > FAP > FAP-H82Q6

Biotinylated Human FAP Protein, His,Avitag™ (MALS verified)

  • Synonym
    FAP,FAPalpha,SIMP,Seprase,APCE
  • Source
    Biotinylated Human FAP Protein, His,Avitag (FAP-H82Q6) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Asp 760 (Accession # Q12884-1).
    Predicted N-terminus: His
  • Molecular Characterization
    Online(Leu 26 - Asp 760) Q12884-1

    This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 93.1 kDa. The protein migrates as 100-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human FAP Protein, His,Avitag (Cat. No. FAP-H82Q6) SDS-PAGE gel

Biotinylated Human FAP Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Biotinylated Human FAP Protein, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human FAP Protein, His,Avitag (Cat. No. FAP-H82Q6) was more than 90% and the molecular weight of this protein is around 200-230 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human FAP Protein, His,AvitagBiotinylated Human FAP Protein, His,Avitag (Cat. No. FAP-H82Q6) ELISA bioactivity

Immobilized Biotinylated Human FAP Protein, His,Avitag (Cat. No. FAP-H82Q6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Sibrotuzumab with a linear range of 0.1-1 ng/mL (QC tested).

Bioactivity

Measured by its ability to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4-methylcoumarin (Z-GP-AMC) to Z-Gly-Pro and 7-amino-4-methylcoumarin (AMC). The specific activity is >4000 pmol/min/µg (QC tested).

  • Background
    FAP (also known as seprase) is a Type II transmembrane serine protease. Both plasma membrane and soluble forms exhibit post-proline cleaving endopeptidase activity, with a marked preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences. Degrade also gelatin, heat-denatured type I collagen. Also has dipeptidyl peptidase activity, with a preference for Ala-Pro, Ile-Pro, Gly-Pro, Arg-Pro and Pro-Pro. The plasma membrane form, in association with either DPP4, PLAUR or integrins, is involved in the pericellular proteolysis of the extracellular matrix (ECM), and hence promotes cell adhesion, migration and invasion through the ECM. Promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. Acts as a tumor suppressor in melanocytic cells through regulation of cell proliferation and survival in a serine protease activity-independent manner.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $319.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:4 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop